Knight Therapeutics (TSE:GUD) Reaches New 1-Year High - Time to Buy?

Key Points

• Knight Therapeutics' stock hit a new 52-week high of C$8.04 intraday and was last around C$7.86, trading above its 50-day (C$6.99) and 200-day (C$6.34) moving averages, indicating recent upward momentum.
• Despite C$147.6M in quarterly revenue and C$0.13 EPS, the company shows profitability concerns with a negative P/E (-166.4), a slightly negative net margin and return on equity, and a high debt-to-equity ratio (10.15).
• Knight Therapeutics is a specialty and generic drug company that also finances other life‑sciences firms to generate interest income and secure product distribution rights, reflecting a mix of commercial and financing activities in its business model.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as C$8.04 and last traded at C$7.86, with a volume of 37887 shares changing hands. The stock had previously closed at C$7.51.

Knight Therapeutics Stock Performance

The company has a debt-to-equity ratio of 10.15, a current ratio of 2.39 and a quick ratio of 1.79. The company has a market capitalization of C$815.83 million, a PE ratio of -166.40, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.21. The firm's fifty day simple moving average is C$6.99 and its 200 day simple moving average is C$6.34.

Knight Therapeutics (TSE:GUD - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%. The company had revenue of C$147.59 million for the quarter. On average, research analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.